LIVIVO - Search results -

Search results

Result 1 - 10 of total 74

Search options

Article ; Online: Cariprazine: A Review in Schizophrenia.

Garnock-Jones, Karly P

2017 Volume 31, Issue 6, Page(s) 513–525

Abstract: Cariprazine (Vraylar™) is a dopamine ... ...

Abstract	Cariprazine (Vraylar™) is a dopamine D
Language	English
Publishing date	2017-06
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	1203800-3
ISSN	1179-1934 ; 1172-7047
ISSN (online)	1179-1934
ISSN	1172-7047
DOI	10.1007/s40263-017-0442-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4083: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Garnock-Jones, Karly P

Drugs

2017 Volume 77, Issue 1, Page(s) 75–83

Abstract: Intravenous dalbavancin ( ... ...

Abstract	Intravenous dalbavancin (Dalvance
MeSH term(s)	Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Dose-Response Relationship, Drug ; Gram-Positive Bacteria/drug effects ; Humans ; Skin Diseases, Infectious/drug therapy ; Skin Diseases, Infectious/microbiology ; Teicoplanin/administration & dosage ; Teicoplanin/analogs & derivatives ; Teicoplanin/pharmacology ; Teicoplanin/therapeutic use
Chemical Substances	Anti-Bacterial Agents ; Teicoplanin (61036-62-2) ; dalbavancin (808UI9MS5K)
Language	English
Publishing date	2017-01
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-016-0666-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.

Garnock-Jones, Karly P

Drugs

2017 Volume 77, Issue 3, Page(s) 319–330

Abstract: Saxagliptin/dapagliflozin fixed-dose combination tablets ( ... ...

Abstract	Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern
MeSH term(s)	Adamantane/administration & dosage ; Adamantane/analogs & derivatives ; Adamantane/therapeutic use ; Benzhydryl Compounds/administration & dosage ; Benzhydryl Compounds/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Dipeptides/administration & dosage ; Dipeptides/therapeutic use ; Glucosides/administration & dosage ; Glucosides/therapeutic use ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/therapeutic use
Chemical Substances	Benzhydryl Compounds ; Dipeptides ; Glucosides ; Hypoglycemic Agents ; dapagliflozin (1ULL0QJ8UC) ; saxagliptin (9GB927LAJW) ; Adamantane (PJY633525U)
Language	English
Publishing date	2017-01-26
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-017-0697-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Erratum to: panobinostat: first global approval.

Garnock-Jones, Karly P

Drugs

2015 Volume 75, Issue 8, Page(s) 929

Language	English
Publishing date	2015-05
Publishing country	New Zealand
Document type	Published Erratum
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-015-0403-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Brexpiprazole: A Review in Schizophrenia.

Garnock-Jones, Karly P

CNS drugs

2016 Volume 30, Issue 4, Page(s) 335–342

Abstract: Oral brexpiprazole (Rexulti(®)) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article reviews the pharmacological properties of brexpiprazole and its clinical efficacy and tolerability in patients with ... ...

Abstract	Oral brexpiprazole (Rexulti(®)) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article reviews the pharmacological properties of brexpiprazole and its clinical efficacy and tolerability in patients with schizophrenia; its use in patients with major depressive disorder is beyond the scope of this review. Brexpiprazole 2-4 mg/day was generally effective in short-term, phase III studies at improving Positive and Negative Symptom Scale scores and other schizophrenia symptoms in patients with acute schizophrenia. Moreover, maintenance treatment with brexpiprazole 1-4 mg/day was associated with a significantly longer time to exacerbation of disease or impending relapse than placebo. The drug was well tolerated in clinical trials, with most serious adverse events in the short term being associated with the underlying disorder. Overall, oral brexpiprazole is a useful treatment option for the treatment of patients with schizophrenia.
MeSH term(s)	Animals ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/pharmacokinetics ; Humans ; Quinolones/administration & dosage ; Quinolones/adverse effects ; Quinolones/pharmacokinetics ; Schizophrenia/drug therapy ; Schizophrenia/metabolism ; Thiophenes/administration & dosage ; Thiophenes/adverse effects ; Thiophenes/pharmacokinetics
Chemical Substances	Antipsychotic Agents ; Quinolones ; Thiophenes ; brexpiprazole (2J3YBM1K8C)
Language	English
Publishing date	2016-04
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	1203800-3
ISSN	1179-1934 ; 1172-7047
ISSN (online)	1179-1934
ISSN	1172-7047
DOI	10.1007/s40263-016-0325-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4083: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Prucalopride: A Review in Chronic Idiopathic Constipation.

Garnock-Jones, Karly P

Drugs

2016 Volume 76, Issue 1, Page(s) 99–110

Abstract: Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief. This ...

Abstract	Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief. This article reviews the pharmacological properties of prucalopride and its clinical efficacy and tolerability in patients with CIC. In five well-designed, 12-week trials in patients with CIC, oral prucalopride 2 mg/day was significantly more effective than placebo at improving bowel function, including the number of bowel movements and a range of other constipation symptoms, as well as health-related quality of life and patient satisfaction; however, no significant differences in bowel function measures were observed between prucalopride and placebo in a 24-week trial. Oral PEG-3350 + electrolytes reconstituted powder was found to be noninferior but not superior to prucalopride according to primary endpoint data from a 4-week, controlled-environment trial. Prucalopride was generally well tolerated in clinical trials; the most common adverse events were headache, diarrhoea, nausea and abdominal pain. No cardiovascular safety issues have arisen with prucalopride treatment. Although further long-term and comparative data would be beneficial, prucalopride provides an additional treatment option for patients with CIC.
MeSH term(s)	Benzofurans/adverse effects ; Benzofurans/pharmacokinetics ; Benzofurans/pharmacology ; Benzofurans/therapeutic use ; Chronic Disease ; Constipation/drug therapy ; Humans ; Laxatives/adverse effects ; Laxatives/pharmacokinetics ; Laxatives/pharmacology ; Laxatives/therapeutic use ; Serotonin 5-HT4 Receptor Agonists/adverse effects ; Serotonin 5-HT4 Receptor Agonists/pharmacokinetics ; Serotonin 5-HT4 Receptor Agonists/pharmacology ; Serotonin 5-HT4 Receptor Agonists/therapeutic use
Chemical Substances	Benzofurans ; Laxatives ; Serotonin 5-HT4 Receptor Agonists ; prucalopride (0A09IUW5TP)
Language	English
Publishing date	2016-01
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-015-0518-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Necitumumab: First Global Approval.

Garnock-Jones, Karly P

Drugs

2016 Volume 76, Issue 2, Page(s) 283–289

Abstract: Eli Lilly is developing necitumumab (Portrazza™), an intravenously administered fully human IgG monoclonal antibody directed against the epidermal growth factor receptor (EGFR), which is expressed in a variety of solid tumours and has been implicated in ... ...

Abstract	Eli Lilly is developing necitumumab (Portrazza™), an intravenously administered fully human IgG monoclonal antibody directed against the epidermal growth factor receptor (EGFR), which is expressed in a variety of solid tumours and has been implicated in promoting oncogenesis and tumour progression. Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication. Necitumumab was derived from the proprietary phage display library of Dyax Corp, and originated with ImClone Systems, which was acquired by Eli Lilly in November 2008. Necitumumab was also under phase II development for colorectal cancer in Belgium and Spain; however, no recent development has been reported for this indication. This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Squamous Cell/drug therapy ; Cisplatin/administration & dosage ; Clinical Trials, Phase II as Topic ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Humans ; Lung Neoplasms/drug therapy ; Receptor, Epidermal Growth Factor/antagonists & inhibitors
Chemical Substances	Antibodies, Monoclonal ; Deoxycytidine (0W860991D6) ; necitumumab (2BT4C47RUI) ; gemcitabine (B76N6SBZ8R) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2016-02
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-015-0537-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.

Garnock-Jones, Karly P

Clinical drug investigation

2016 Volume 36, Issue 5, Page(s) 413–419

Abstract: Fentanyl buccal soluble film (Onsolis(®), Breakyl(®), Painkyl™) comprises two layers: a mucoadhesive layer containing the active drug, and an inactive layer with the aim of preventing the diffusion of fentanyl into the oral cavity. It is approved in ... ...

Abstract	Fentanyl buccal soluble film (Onsolis(®), Breakyl(®), Painkyl™) comprises two layers: a mucoadhesive layer containing the active drug, and an inactive layer with the aim of preventing the diffusion of fentanyl into the oral cavity. It is approved in several countries worldwide, including the USA and those of the EU, for the management of breakthrough cancer pain in opioid-tolerant, adult patients with cancer. This article reviews the pharmacological properties of fentanyl buccal soluble film and its clinical efficacy and tolerability in these patients. Fentanyl buccal soluble film provides an additional option for transmucosal delivery of fentanyl, with approximately half of the dose undergoing an initial, rapid absorption via the buccal mucosa (accounting for its high bioavailability). In clinical trials, fentanyl buccal soluble film was associated with significant improvements in pain intensity scores versus placebo and was generally well tolerated. The most common adverse events were typical opioid-associated adverse events, such as nausea and vomiting. Fentanyl buccal soluble film is a useful option for the treatment of breakthrough cancer pain in opioid-tolerant patients.
MeSH term(s)	Administration, Buccal ; Analgesics, Opioid/administration & dosage ; Breakthrough Pain/diagnosis ; Breakthrough Pain/drug therapy ; Breakthrough Pain/epidemiology ; Disease Management ; Fentanyl/administration & dosage ; Humans ; Mouth Mucosa/drug effects ; Nausea/chemically induced ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/epidemiology ; Pain Measurement/drug effects ; Randomized Controlled Trials as Topic/methods ; Solubility ; Vomiting/chemically induced
Chemical Substances	Analgesics, Opioid ; Fentanyl (UF599785JZ)
Language	English
Publishing date	2016-05
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	1220136-4
ISSN	1179-1918 ; 0114-2402 ; 1173-2563
ISSN (online)	1179-1918
ISSN	0114-2402 ; 1173-2563
DOI	10.1007/s40261-016-0394-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2807: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.

Garnock-Jones, Karly P

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

2016 Volume 30, Issue 5, Page(s) 461–468

Abstract: Talimogene laherparepvec (Imlygic™) is a first-in-class oncolytic viral immunotherapy derived from herpes simplex virus type 1, which has been genetically modified to increase tumour selectivity and stimulate antitumour immune response. This article ... ...

Abstract	Talimogene laherparepvec (Imlygic™) is a first-in-class oncolytic viral immunotherapy derived from herpes simplex virus type 1, which has been genetically modified to increase tumour selectivity and stimulate antitumour immune response. This article reviews the pharmacological properties of intralesional talimogene laherparepvec and its clinical efficacy and tolerability in patients with unresectable metastatic melanoma. In the phase III OPTiM trial, talimogene laherparepvec was more effective than subcutaneous human granulocyte-macrophage colony-stimulating factor (GM-CSF), both in patients with stage IIIB-IV melanoma [intention-to-treat (ITT) population] and in those with stage IIIB-IVM1a disease (in an exploratory subgroup analysis). Durable response rate (DRR) was significantly higher with talimogene laherparepvec in the ITT population; beneficial results in DRR were also observed in talimogene laherparepvec recipients in patients with stage IIIB-IVM1a disease. Talimogene laherparepvec was generally well tolerated in clinical trials. In conclusion, talimogene laherparepvec is a novel, effective and well tolerated option for the treatment of patients with unresectable metastatic melanoma.
MeSH term(s)	Dose-Response Relationship, Immunologic ; Herpesvirus 1, Human/immunology ; Humans ; Immunotherapy/methods ; Melanoma/pathology ; Melanoma/therapy ; Oncolytic Virotherapy/methods ; Oncolytic Viruses/immunology ; Tissue Distribution ; Treatment Outcome
Language	English
Publishing date	2016-10
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	1364202-9
ISSN	1179-190X ; 1173-8804
ISSN (online)	1179-190X
ISSN	1173-8804
DOI	10.1007/s40259-016-0189-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4112: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.

Garnock-Jones, Karly P

Drugs

2016 Volume 76, Issue 14, Page(s) 1365–1372

Abstract: Intravenous fosaprepitant dimeglumine (Emend(®) for injection, IVEmend(®); henceforth referred to as fosaprepitant) is a prodrug of and is rapidly converted to the antiemetic aprepitant, and is approved in several countries worldwide (as part of an ... ...

Abstract	Intravenous fosaprepitant dimeglumine (Emend(®) for injection, IVEmend(®); henceforth referred to as fosaprepitant) is a prodrug of and is rapidly converted to the antiemetic aprepitant, and is approved in several countries worldwide (as part of an antiemetic regimen) for the prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy (HEC and MEC). This narrative review discusses the pharmacological properties of intravenous fosaprepitant and its clinical efficacy and tolerability in the prevention of nausea and vomiting associated with HEC and MEC. In large, randomized phase III clinical trials, a single intravenous dose of fosaprepitant 150 mg was an effective and generally well tolerated addition to an antiemetic regimen that included dexamethasone and a serotonin 5-HT3 receptor antagonist in adult cancer patients undergoing treatment with HEC or MEC. It was also noninferior to an oral aprepitant-based regimen in adult cancer patients undergoing HEC treatment. The tolerability profile of a fosaprepitant-based regimen was typical of that in patients receiving emetogenic chemotherapy, and adverse events were generally consistent with those observed with an aprepitant-based regimen. Fosaprepitant provides a useful addition to antiemetic therapy regimens.
MeSH term(s)	Animals ; Antiemetics/pharmacology ; Antiemetics/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase III as Topic ; Humans ; Morpholines/pharmacology ; Morpholines/therapeutic use ; Nausea/chemically induced ; Nausea/prevention & control ; Neoplasms/drug therapy ; Vomiting/chemically induced ; Vomiting/prevention & control
Chemical Substances	Antiemetics ; Antineoplastic Agents ; Morpholines ; fosaprepitant (6L8OF9XRDC)
Language	English
Publishing date	2016-09
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-016-0627-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito